Literature DB >> 18192073

The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures.

Jiang Fan1, Lei Wang, Ge-Ning Jiang, Wen-Xin He, Jia-An Ding.   

Abstract

The prognostic value of survivin for survival of patients with non-small cell lung cancer (NSCLC) remains controversial. The authors performed a meta-analysis of the literatures in order to clarify its impact. Published studies were identified using an electronic search in order to aggregate the available survival results. To be eligible, a study had to have dealt with survivin assessment in NSCLC patients on the primary site and have analyzed survival according to survivin expression. There were 10 eligible studies and data from eight studies where non-location specific immunohistochemistry (IHC) definition system, in situ hybridization (ISH) and RT-PCR used were combined to present the impact of survivin on overall survival (OS) of NSCLC. The level of survivin expression correlated with the OS of NSCLC patients significant (RR 1.88, 95% CI 1.31-2.70, P=0.0006). Data of seven studies were combined to demonstrate that the level of survivin correlated with the OS of NSCLC patients who had received radical surgeries (RR 1.79, 95% CI 1.45-2.20, P<0.00001). Data from three studies were combined to find that the level of nuclear survivin did not have impact on OS of NSCLC patients (RR 1.58, 95% CI 0.87-2.85, P=0.13). Positive-survivin expression might be a prognostic factor for NSCLC patients, nuclear survivin positivity could not work as a prognostic factor for NSCLC patients based on current clinical data. Larger clinical trails with widely accepted assessment methods are necessary to define the precise prognostic significance for survivin in NSCLC patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18192073     DOI: 10.1016/j.lungcan.2007.11.011

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  22 in total

1.  The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin.

Authors:  Anjaiah Srirangam; Monica Milani; Ranjana Mitra; Zhijun Guo; Mariangellys Rodriguez; Hitesh Kathuria; Seiji Fukuda; Anthony Rizzardi; Stephen Schmechel; David G Skalnik; Louis M Pelus; David A Potter
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

2.  PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis.

Authors:  Ze-Jun Zhou; Ping Zhan; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2015-04

3.  Prognostic significance of preoperative serum carcinoembryonic antigen in non-small cell lung cancer: a meta-analysis.

Authors:  Xiao-Bin Wang; Jie Li; Yi Han
Journal:  Tumour Biol       Date:  2014-07-15

4.  Survivin expression is an independent poor prognostic marker in lung adenocarcinoma but not in squamous cell carcinoma.

Authors:  Ping-Li Sun; Yan Jin; Hyojin Kim; An Na Seo; Sanghoon Jheon; Choon-Taek Lee; Jin-Haeng Chung
Journal:  Virchows Arch       Date:  2013-08-02       Impact factor: 4.064

5.  Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables.

Authors:  Thierry Berghmans; Marianne Paesmans; Jean-Paul Sculier
Journal:  Ther Adv Med Oncol       Date:  2011-05       Impact factor: 8.168

6.  The role of SOX-2 on the survival of patients with non-small cell lung cancer.

Authors:  Wenlong Shao; Hanzhang Chen; Jianxing He
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

7.  Expression of survivin and patients survival in non-small cell lung cancer: a meta-analysis of the published studies.

Authors:  Li-Nian Huang; Dong-Sheng Wang; Yu-Qing Chen; Cheng-Ling Zhao; Bei-Lei Gong; An-Bang Jiang; Wei Jia; Feng-Dan Hu
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

8.  Nuclear survivin expression: a prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer.

Authors:  Yao-Kuang Wu; Chun-Yao Huang; Mei-Chen Yang; Chou-Chin Lan; Chih-Hsin Lee; Err-Cheng Chan; Kuei-Tien Chen
Journal:  Med Oncol       Date:  2014-06-25       Impact factor: 3.064

9.  Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Ping Zhan; Qian Qian; Li-Ke Yu
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

10.  Combination of p53AIP1 and survivin expression is a powerful prognostic marker in non-small cell lung cancer.

Authors:  Shin-ichi Yamashita; Masao Chujo; Michiyo Miyawaki; Keita Tokuishi; Kentaro Anami; Satoshi Yamamoto; Katsunobu Kawahara
Journal:  J Exp Clin Cancer Res       Date:  2009-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.